-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
2026-04-10
Good News! On the same day, two products—Metoclopramide Hydrochloride Injection (2 mL: 10 mg) and Compound Electrolyte Sodium Acetate Glucose Injection (250 mL and 500 mL)—from Shijiazhuang Sihua Pharmaceutical Group were approved.
Innovation Brings Good News. On April 10, Shijiazhuang Sihua Pharmaceutical Group’s applications for Class 3 chemical drugs—metoclopramide hydrochloride injection (2 mL: 10 mg) and compound electrolyte sodium acetate-glucose injection (250 mL and 500 mL)—were approved by the National Medical Products Administration for manufacturing registration and are deemed to have passed the consistency evaluation. Since the beginning of this year, the Group has received approval for a total of 21 new products.
2026-04-03
Shijiazhuang Sihua Pharmaceutical Group’s Tranexamic Acid Tablets (0.25 g) Have Been Approved
On April 3, Shijiazhuang Sihua Pharmaceutical Group’s Class 4 chemical drug—tranexamic acid tablets (0.25 g)—received production registration approval from the National Medical Products Administration and is deemed to have passed the bioequivalence evaluation. This marks the group’s 10th newly approved dosage-form product so far this year. To date, the group has a total of 173 drug varieties comprising 226 specifications that have either passed or are deemed to have passed the bioequivalence evaluation for generic drugs in terms of quality and therapeutic efficacy.
2026-03-30
Shijiazhuang Sihua Pharmaceutical Group’s Guolong Pharmaceutical Receives Approval for Upadacitinib API
On March 30, the upadacitinib API developed by Hebei Guolong Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, successfully changed its registration status to “A” at the Center for Drug Evaluation of the National Medical Products Administration, thereby qualifying as an API for use in marketed dosage forms. This marks the eighth specialized API product approved by the Group this year.
Dedication and boldness in striving for excellence, coupled with innovation, herald the early arrival of spring. On March 27, Shijiazhuang Sihua Pharmaceutical Group’s applications for Class 3 chemical drugs—sodium lactate Ringer’s irrigation solution (3,000 ml) and bumetanide injection (2 ml: 1 mg)—were approved by the National Medical Products Administration for manufacturing registration and are deemed to have passed the consistency evaluation.
27
2026/03
On March 23, Shijiazhuang Sihua Pharmaceutical Group received approval from the National Medical Products Administration for the registration of an expanded indication for its Class 3 chemical drug—magnesium sulfate injection (10 mL: 2.5 g). This marks the group’s seventh new dosage-form product approved so far this year.
23
2026/03
On March 19, the calcium chloride active pharmaceutical ingredient developed by Hebei Guolong Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, successfully changed its registration status to “A” at the Center for Drug Evaluation of the National Medical Products Administration, thereby qualifying as an API for use in marketed dosage forms. To date this year, the Group has received approval for seven new specialty APIs.
19
2026/03
On March 16, the bumetanide API developed by Hebei Guolong Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, successfully changed its registration status to “A” at the Center for Drug Evaluation of the National Medical Products Administration, thereby qualifying as an API used in marketed dosage forms. Since the beginning of this year, the Group has received approval for a total of six new specialty APIs.
16
2026/03
Innovative achievements are already bearing fruit in early spring. On March 13, the Class 3 liposoluble vitamin injection (II) developed and submitted for approval by Shijiazhuang Sihua Pharmaceutical Group received production registration approval from the National Medical Products Administration and is deemed to have passed the consistency evaluation, making the company one of the first in China to obtain such approval. This marks the group’s sixth newly approved dosage-form product so far this year.
13
2026/03
Shijiazhuang Sihua Pharmaceutical Group’s Calcium Leucovorin for Injection Approved
Spring is the best time of year, and now is the perfect moment to forge ahead. On March 6, Shijiazhuang Sihua Pharmaceutical Group’s Class 3 chemical drug—calcium leucovorin for injection (25 mg, calculated on the basis of C20H23N7O7)—received production registration approval from the National Medical Products Administration and is deemed to have passed the consistency evaluation. This marks the group’s 10th newly approved product so far this year.
09
2026/03
Good news on a festive occasion heralds a new chapter of innovation. On March 3, Shijiazhuang Sihua Pharmaceutical Group’s Class 3 chemical drug—Doxapram Hydrochloride Injection (5 ml: 100 mg)—received production registration approval from the National Medical Products Administration and is deemed to have passed the consistency evaluation, making the company the first in China to obtain approval for this product. Since the beginning of this year, the Group has secured approval for nine new products.
09
2026/03
On February 27, the active pharmaceutical ingredients metoclopramide hydrochloride and metoclopramide, developed by Hebei Guangxiang Pharmaceutical Co., Ltd. of Shijiazhuang Sihua Pharmaceutical Group, successfully had their registration status at the Center for Drug Evaluation of the National Medical Products Administration changed to “A,” thereby qualifying as APIs for use in marketed dosage forms. Since the beginning of this year, the Group has received approval for a total of five new specialty API products.
27
2026/02
Recently, two medical device products developed by Hebei Hanlin Biotechnology Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group—namely, a medical-grade recombinant collagen gynecological gel and a B-type natriuretic peptide (BNP) assay kit (fluorescent immuno-chromatographic assay)—have been granted Medical Device Registration Certificates by the Hebei Provincial Drug Administration. This marks a new milestone in Hanlin Biotechnology’s product portfolio development and innovation in the fields of medical consumables and in vitro diagnostics.
27
2026/02
As the festive season arrives, good news follows. On February 13, the propranolol hydrochloride API developed by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, successfully had its registration status at the Center for Drug Evaluation of the National Medical Products Administration changed to “A,” signifying its approval for use in marketed dosage forms. This marks the third specialized API new product approved for the Group since the start of the year and the sixth new product overall achieved by the Group.
25
2026/02
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091